Healthcare
Live Price
Offline$9.38
+0.32% today
1Y Change
-65.40%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phreesia, Inc. (PHR) is a Healthcare stock with a market cap of $590.00M and listed on NYSE. The stock last traded around $9.38 and down 65.4% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +14.5%, EPS growth of +103.8%, a dividend yield of 0.0%. What stands out right now is revenue +14.5%, EPS +103.8%, free cash flow +716.6% with operating margin -1.4% and ROIC 0.3%. Valuation already assumes a fairly strong business story at P/E 250.5 and price/sales 1.2. Stock Foundry combines PHR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHR Max Drawdown
-75.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$213.2M
-24.1% YoY
FY Net Income
-$118.2M
+32.9% YoY
Free Cash Flow
-$105.5M
+9.3% YoY
Revenue Growth
+14.5%
EPS Growth
+103.8%
Gross Margin
61.3%
Net Margin
0.5%
Income statement
USD
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 481M | 420M | 356M | 281M | 213M |
| Gross Profit | 409M | 285M | 232M | 172M | 132M |
| Operating Income | 108M | -58M | -136M | -177M | -117M |
| EBITDA | 29M | -26M | -103M | -145M | -92M |
| Net Income | -20M | -59M | -137M | -176M | -118M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74M | 84M | 88M | 177M | 314M |
| Total Assets | 664M | 388M | 370M | 370M | 494M |
| Total Liabilities | 327M | 124M | 119M | 82M | 77M |
| Shareholder Equity | 337M | 265M | 251M | 288M | 417M |
| Total Debt | 102M | 18M | 12M | 9M | 16M |
| Net Debt | 29M | -66M | -76M | -168M | -298M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
75M
+17.1% YoY
Capital Expenditures
31M
-17.6% YoY
Free Cash Flow
106M
+9.3% YoY
Key ratios
Gross Margin
61.3%
Operating Margin
-1.4%
Net Margin
0.5%
ROE
0.7%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.